Fezagepras

Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].

Product Specifications

CAS Number

[1002101-19-0]

Product Name Alternative

Setogepram; PBI-4050

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Free Fatty Acid Receptor; GPR84

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/setogepram.html

Purity

99.38

Solubility

DMSO : 60 mg/mL (ultrasonic; warming)

Smiles

O=C(CC1=CC=CC(CCCCC)=C1)O

Molecular Formula

C13H18O2

Molecular Weight

206.28

Precautions

H302, H312, H332

References & Citations

[1]Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3 (10) . pii: 120365.|[2]Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367 (1) :71-81.